<DOC>
	<DOCNO>NCT02171702</DOCNO>
	<brief_summary>The primary objective study identify maximum tolerate dose evaluate safety , pharmacokinetics , pharmacodynamic parameter , efficacy BIBW 2992 .</brief_summary>
	<brief_title>Dose Escalation Study Oral Treatment With BIBW 2992 Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<criteria>Male female patient confirm diagnosis advance , nonresectable / metastatic solid tumour , type historically know express EGFR and/or HER2 , fail conventional treatment , therapy proven efficacy exists , amenable establish form treatment preferably patient breast , colorectal prostate cancer Age 18 year old Life expectancy least three ( 3 ) month Written inform consent consistent International Conference Harmonization Good Clinical Practice guideline Eastern Cooperative Oncology Group ( ECOG ) performance score 0 , 1 2 Patients completely recover therapyrelated toxicity previous chemo , hormone , immuno , radiotherapy CTC &lt; = Grade 1 Patients must recover previous surgery The 12 additional patient recruit MTD must also meet follow criterion : Measurable tumour deposit ( RECIST ) one technique ( Xray , CT , MRI ) and/or recognize tumour marker prostatespecific antigen prostate cancer ) cancer antigen 125 ( Ovarian cancer ) Active infectious disease Gastrointestinal disorder may interfere absorption study drug chronic diarrhea Serious illness concomitant nononcological disease consider investigator incompatible protocol Patients untreated symptomatic brain metastasis . Patients treat , asymptomatic brain metastasis eligible change brain disease status least eight ( 8 ) week , history cerebral edema bleed past eight ( 8 ) week requirement steroid antiepileptic therapy Cardiac leave ventricular function rest ejection fraction CTC &gt; = Grade 1 Absolute neutrophil count ( ANC ) less 1500 / mm3 Platelet count less 100 000 / mm3 Bilirubin great 1.5 mg /dl ( &gt; 26 μmol /L , Système Internationale ( SI ) unit equivalent ) Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) great three time upper limit normal ( related liver metastasis great five time upper limit normal ) Serum creatinine great 1.5 mg / dl ( &gt; 132 μmol / L , SI unit equivalent ) Women men sexually active unwilling use medically acceptable method contraception Pregnancy breastfeed Treatment investigational drug ; chemotherapy , immunotherapy , radiotherapy hormone therapy ( exclude Luteinizing HormoneReleasing Hormone agonist , hormone take breast cancer , bisphosphonates ) , participation another clinical study within past 4 week start therapy concomitantly study Treatment EGFR HER2 inhibit drug within past four week start therapy concomitantly study ( 8 week trastuzumab ) Patients unable comply protocol Active alcohol drug abuse A patient may eligible retreatment previous course finish . A patient eligible follow condition meet . Patients clinical sign disease progression late Xray , CT MRI reveal Progressive Disease Cardiac leave ventricular function CTC &gt; = Grade 2 time previous course Patients fulfil Exclusion Criteria list determined treatment Day 28 , R5 previous course Patient recover doselimiting toxicity 14 day last administration BIBW 2992 previous course . Recovery define return baseline level CTC Grade 1 , whichever high</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>